Novo Nordisk A/S (NOVOb.CO)
23 May 2018
* EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION
French gas and power group Engie , Polish gas firm PGNiG and German lender DZ Bank were the latest companies on Friday to say that their business dealings with Iran would be affected by the re-imposition of U.S. sanctions.
A.P. Moller-Maersk, the world's biggest container shipper, said on Thursday it planned to shut down operations in Iran.
President Donald Trump on Tuesday pulled the United States out of the 2015 international nuclear deal with Iran, raising the risk of conflict in the Middle East, upsetting European allies and casting uncertainty over global oil supplies.
* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION
BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme
* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME
COPENHAGEN Novo Nordisk , the world's biggest maker of diabetes drugs, reported a smaller than expected fall in first-quarter profit and nudged up its full-year forecast as sales of new medicines helped to soften the hit from a weaker U.S. dollar.
* U.S. legislation puts pressure on 2019 sales (Adds CEO quotes, share price)
May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:
COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.